Enanta Pharmaceuticals Posts Q2 Loss of $0.45, Shares Jump 5.3%
Enanta reported a fiscal Q2 net loss of $0.45 per share for the quarter ended March 31, 2026, compared with a $1.06 loss a year earlier and marginally missing the consensus loss estimate of $0.46. Revenue also fell short of analyst forecasts, triggering a 5.3% share rally post-release.
1. Fiscal Second Quarter Results
For the quarter ended March 31, 2026, Enanta Pharmaceuticals recorded a net loss of $0.45 per share, an improvement from a $1.06 per-share loss in the same period last year. The result slightly missed the consensus estimate of a $0.46 loss, as revenues fell below analyst expectations.
2. Share Price Movement
Following the earnings release, shares of Enanta Pharmaceuticals rose 5.3% as investors reacted to the improved year-over-year loss and weighed the revenue shortfall against the company’s financial trajectory.